Clinical Trials Logo

Hyperprolactinemia clinical trials

View clinical trials related to Hyperprolactinemia.

Filter by:

NCT ID: NCT01117272 Completed - Clinical trials for Polycystic Ovary Syndrome

The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women

Start date: May 2009
Phase: N/A
Study type: Observational

Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder of reproductive-age women. According to Rotterdam 2003 criteria: at least two of three criteria are met, hyperandrogenism, chronic anovulation, and polycystic ovary. PCOS will cause irregular menstrual cycle, infertility, acne, hirsutism, obesity, or/and metabolic syndrome, diabetes that may increase risk of cardiovascular disease. Hyperprolactinaemia is also a common problem in reproductive aged women. Both hyperprolactinaemia and PCOS had endocrine disorder and irregular menstrual cycle. Investigators hope to collect clinical data from PCOS and prolactinemia patients followed in Wang Fang hospital for many years in endocrinological and metabolical aspects for comparison. Investigators at the same time would like to understand more about other similarities and differences between these two endocrinological dysfunction for future study.

NCT ID: NCT01085383 Completed - Hyperprolactinemia Clinical Trials

Aripiprazole and Prolactin Study

APS
Start date: April 2010
Phase: Phase 4
Study type: Interventional

Antipsychotic medicines are used routinely in people with severe mental illness or learning disability. Antipsychotics often induce hyperprolactinemia (high prolactin level) and in almost all women, and some men, this causes hypogonadism (impaired ovarian or testicular function)often with osteoporosis, partly explaining psychiatric patients' high fracture risk. Reducing prolactin by changing antipsychotic or adding a dopamine agonist often worsens psychosis. Adding aripiprazole to current antipsychotic normalizes prolactin in adult schizophrenic patients, without serious side effects. We thus plan a study of add-on aripiprazole in people with antipsychotic induced hyperprolactinemia. Our main hypothesis is that aripiprazole will normalize or reduce prolactin sufficiently to restore normal ovarian and testicular function. Our secondary hypothesis is that restoration of normal ovarian and testicular function will improve bone mineral density in patients in whom this was reduced at the time of entry into the study.

NCT ID: NCT01052948 Completed - Parkinson's Disease Clinical Trials

The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events

Start date: January 2007
Phase: N/A
Study type: Observational

To assess the association between cabergoline and other dopamine agonists (DAs), and symptomatic, diagnosed serious cardiopulmonary disorders, including: 1. Cardiac valve regurgitation 2. Diffuse Pleural/pulmonary thickening and pericardial and retroperitoneal fibrosis 3. Heart failure 4. Total, cardiac and respiratory mortality

NCT ID: NCT00952757 Completed - Schizophrenia Clinical Trials

Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine

Start date: June 2007
Phase: N/A
Study type: Observational

Hyperprolactinaemia is a common side effect of some antipsychotics (APS), including some atypicals. Clinical consequences of hyperprolactinaemia are broad including amenorrhea, galactorrhea, tender breasts, gynecomastia and sexual dysfunction. Less known but also present is the increased cardiovascular risk, specially in women, disorders of osteoporotic type and a potential increased risk of breast and prostate cancer. Despite this growing evidence, there are no consistent published data in order to adopt evidence-based decisions that may be beneficial for the patient. This naturalistic observational 6 months follow-up study on patients with APS-induced hyperprolactinemia aims to obtain more information about the switching approach in cases of hyperprolactinemia secondary to APS and to better establish the role of switching to quetiapine (APS not related with the increase prolactin levels) in this problem.

NCT ID: NCT00799383 Completed - Clinical trials for Risperidone-induced Hyperprolactinemia

Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia

Start date: November 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether calcium and vitamin D supplementation, over a nine-month period, optimizes bone mineralization in boys with risperidone-induced hyperprolactinemia. We hypothesize that, by the end of the stuy, children in the supplementation group will have higher bone mineral density compared to those in the placebo group.

NCT ID: NCT00625950 Completed - Endometriosis Clinical Trials

Endometriosis Patients Undergoing Quinagolide Treatment

Start date: February 2008
Phase: Phase 4
Study type: Interventional

Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.

NCT ID: NCT00436111 Completed - Hyperprolactinemia Clinical Trials

Characterization of Macroprolactinemia

Start date: January 2005
Phase: N/A
Study type: Observational

The purpose of this study is to clarify the nature of macroprolactin which has recently been highlighted because of the high prevalence and a diagnostic pitfall of hyperprolactinemia. The results of this study are beneficial for the patients to whom unnecessary medications and unnecessary radiological examinations have been performed. We used the remained serum samples taken for routine prolactin determination during the past several years. Since the blood was basically taken to examine the causes of hyperprolactinemia and only remained serum samples were used for this study, the Ethics Committee of Kobe City General Hospital judged that it was not required to obtain approval number.